Improving Science & Restoring Trust in Public Health | Dr. Jay Bhattacharya
Summary
Dr. Jay Bhattacharya, Director of the National Institutes of Health and former Stanford Professor of Health Policy, discusses the structural problems plaguing American biomedical research funding, the erosion of public trust in science following COVID-19 policy failures, and his vision for reforming the NIH. The conversation covers how taxpayer dollars flow through universities, why Americans pay dramatically more for prescription drugs than the rest of the world, and what concrete changes are underway to make science more transparent, innovative, and accountable.
Key Takeaways
- American life expectancy has been stagnant since 2012 — while European countries showed gains, the U.S. flatlined before the pandemic and only recovered to 2019 levels in 2024, indicating the current biomedical research model is not meeting its core mission.
- NIH-funded research papers will be freely available to the public starting July — accelerating a policy initiated by the previous NIH director, ensuring taxpayers can read the science they paid for without purchasing journal subscriptions.
- Americans pay 2–10x more for the same drugs as Europeans, effectively subsidizing global pharmaceutical R&D through higher drug prices — an arrangement Dr. Bhattacharya calls unsustainable.
- The NIH peer review (study section) system structurally favors incremental, “safe” science over bold, high-risk hypotheses — a key reason the agency has generated fewer breakthrough discoveries in recent decades.
- Basic research will remain a protected priority at the NIH under the current director — fears of it being gutted in favor of applied-only research are unfounded, according to Dr. Bhattacharya.
- The replication crisis is being actively addressed through new NIH initiatives designed to verify findings early and incentivize replication, ensuring the knowledge base is accurate.
- Indirect cost (IDC) structures concentrate research funding on coastal elite universities, disadvantaging equally talented scientists at less wealthy institutions — a structural problem the administration is reconsidering.
- Geographic and intellectual diversity in science funding combats groupthink and produces richer, more innovative science.
- The current drug patent and pricing system (shaped by the Bayh-Dole Act) was designed to accelerate translation of basic science into usable treatments, but has resulted in Americans funding the world’s pharmaceutical R&D pipeline with little direct benefit.
Detailed Notes
NIH Mission and the Role of Basic Research
- The stated mission of the NIH is to advance the health and longevity of the American people.
- The NIH is considered the world’s premier biomedical research institution, with a role in developing nearly every approved drug and health guideline.
- A substantial portion of the NIH budget funds basic research — discoveries made without a specific disease or treatment in mind.
- Historical examples of basic research with enormous downstream impact:
- Watson, Crick, Franklin, and the double helix — unpatenatable at the time, yet foundational to all of modern biology.
- Hubel and Wiesel’s visual cortex studies — led directly to early corrective surgery protocols for cataracts, strabismus, and drooping eyelids in children, saving the vision of millions.
- Cell biology and mitochondria research — laid the necessary groundwork for essentially all modern cancer treatments.
- Dr. Bhattacharya explicitly confirmed: basic science will remain a core part of the NIH portfolio under his leadership; no directive from the current administration has suggested otherwise.
The Replication Crisis
- The replication crisis refers to scientific findings that cannot be independently reproduced.
- New NIH initiatives are being developed to verify findings early in the research process and to incentivize replication studies, with the goal of ensuring the scientific knowledge base is reliable.
Open Access to Research
- Under previous NIH director Monica Bertagnolli, a policy was established requiring that NIH-funded research be freely available to the public upon publication — previously scheduled for December 2025.
- Dr. Bhattacharya moved the implementation date to July 2025.
- Currently, journals such as Nature charge approximately **30–$100 per article — despite that research having been funded by taxpayers.
- This open-access shift is framed as essential not just for fairness but for public engagement with science.
Indirect Costs (IDC) and Research Infrastructure
- When a scientist receives an NIH grant (e.g., 550,000 per $1M grant).
- Indirect costs are meant to cover fixed infrastructure expenses: buildings, radioactive material disposal, lab maintenance, administrative handling.
- The Trump administration attempted to cap IDC at a flat 15% across all institutions — this was subsequently blocked by court order and is currently in litigation (Dr. Bhattacharya declined to comment on the legal matter itself).
- Key structural problems with the current IDC model:
- Creates a ratchet effect: you need grants to get IDC support, but you need infrastructure to attract grant-winning scientists.
- Concentrates federal research dollars at a small number of elite, predominantly coastal universities.
- Does not differentiate between high fixed-cost labs (e.g., wet labs with radioactive materials) and low fixed-cost “laptop labs” (e.g., epidemiology, health economics).
- The EPSCOR/IDEAS program provides a competitive advantage to research institutions in the bottom 25 states by NIH funding distribution — Dr. Bhattacharya endorsed this as a tool to counteract geographic concentration.
Peer Review, Scientific Groupthink, and Incentivizing Bold Science
- NIH grants are evaluated by study sections — panels of expert peers who score proposals and advocate for those they find most meritorious.
- The system’s structure embeds conservatism: reviewers implicitly favor grants likely to succeed, which means funding incremental (“turning the crank”) science over bold, high-risk hypotheses.
- Contrast with venture capital model: in Silicon Valley, a portfolio where 49 of 50 bets fail but one becomes transformative is considered highly successful. The NIH model incentivizes the opposite.
- Dr. Bhattacharya referenced a Salk Institute scientist’s framing: two types of science — testing bold hypotheses (most will fail, but hits are spectacular) vs. incremental work (reliable, but low-impact portfolio-wide).
- Geographic diversity in study sections partially mitigates coastal groupthink, but does not fully solve the innovation problem.
American Life Expectancy and the Chronic Disease Crisis
- U.S. life expectancy was essentially flat from 2012–2019, while European countries continued to improve.
- Life expectancy dropped sharply during the pandemic and only returned to 2019 levels in 2024.
- Sweden’s life expectancy dipped in 2020 but recovered to its prior upward trend by 2021–2022.
- Despite significant biomedical advances, the U.S. has failed to address its chronic disease crisis — obesity, depression, metabolic disease — which drives much of the life expectancy gap.
- The current generation of American children is projected to live shorter, less healthy lives than their parents.
- Dr. Bhattacharya characterized the entire industry’s focus on disease management over prevention as an indictment of current priorities.
Drug Pricing: Why Americans Pay More
- Americans pay 2–10x more for the same prescription drugs as Europeans.
- The reason involves an implicit global arrangement:
- NIH (taxpayers) funds basic and applied research.
- Drug companies fund late-stage Phase 3 clinical trials, but recover those costs through premium U.S. pricing.
- European countries negotiate prices at or near marginal cost, contributing little to R&D expenses.
- The Bayh-Dole Act (1980s) enabled patents on NIH-funded discoveries to incentivize the private sector to develop basic findings into marketable treatments — a deliberate trade-off between price and speed of translation.
- Result: American taxpayers are the primary financiers of the global pharmaceutical R&D pipeline.
- Drug company profits are estimated at two-thirds to three-quarters from the U.S. market.
- Drug company R&D naturally aligns to American health problems (obesity, depression, metabolic disease) rather than a